Prediction of no reflow phenomenon in percutaneous coronary intervention with optical coherence tomography and analysis of risk factors
DOI:
https://doi.org/10.1532/hsf.5237Abstract
Objective :To investigate the predictive value of no reflow phenomenon in interventional therapy by measuring plaque quantitatively with optical coherence tomography (OCT).
Methods:196 patients with acute ST segment elevation myocardial infarction who visited the Department of Cardiology of the Second Affiliated Hospital of Zhengzhou University from January 2020 to January 2022 were selected as the study objects. According to whether there was no reflow during the operation, they were divided into no reflow group (46 cases) and normal flow group (150 cases). Systematically collect general clinical data and coronary angiography related data of patients through inpatient cases, measure fiber cap thickness and lipid core angle of diseased vascular plaque through optical coherence tomography, and analyze the relationship between fiber cap thickness and no reflow phenomenon
Results:BMI, LDL, phospholipase A, the proportion of family history of coronary heart disease, and the thrombus load in the no reflow group were higher than those in the normal flow group (P<0.05), while the thickness of the fibrous cap was lower than that in the normal flow group (P<0.05); Further multivariate logistic regression analysis showed that fiber cap thickness, phospholipase A and severe thrombosis load were independent risk factors for non reflow phenomenon (P<0.05); Further ROC curve analysis found that the thickness of fiber cap had a high predictive value for no reflow phenomenon, and the best cutoff value for no reflow was 95, AUC: 0.926 (95% CI: 0.891-0.961, P<0.001).
Conclusions: Optical coherence tomography can predict the occurrence of no reflow phenomenon by measuring the fiber cap thickness quantitatively. The prediction effect is the best when the fiber cap thickness is 95.
References
Amano H, Ikeda T, Toda M, et al. 2016. Plaque Composition and No-Reflow Phenomenon During Percutaneous Coronary Intervention of Low-Echoic Structures in Grayscale Intravascular Ultrasound. Int Heart J. May 25;57(3):285-91.
Avci E, Yildirim T, Aydin G, et al. 2018. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. Aug; 22(15):4987-4994.
Bauer T, Zeymer U, Diallo A, et al. 2020. Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: Results from the ATLANTIC study. Catheter Cardiovasc Interv. Feb 15;95(3):494-500.
Bennett MR, Sinha S, Owens GK. 2016. Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. Feb 19;118(4):692-702.
Bonnefont-Rousselot D. 2016. La Lp-PLA2, marqueur d'inflammation vasculaire et de vulnérabilité de la plaque d'athérosclérose [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques]. Ann Pharm Fr. May;74(3):190-7.
de Vries MR, Parma L, Peters HAB, et al. 2019. Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels. J Intern Med. Jan;285(1):59-74.
Fajar JK, Heriansyah T, Rohman MS. 2018. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. Dec;70 Suppl 3(Suppl 3):S406-S418.
Gupta S, Gupta MM. 2016. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. Jul-Aug;68(4):539-51.
Guidelines for diagnosis and treatment of acute ST segment elevation myocardial infarction. 2019. Chinese Journal of Cardiovascular Diseases. 10.
Hibi K, Kimura K, Umemura S. 2015. Clinical utility and significance of intravascular ultrasound and optical coherence tomography in guiding percutaneous coronary interventions. Circ J. 79(1):24-33.
Huang D, Gao W, Wu R, et al. 2020. D-dimer level predicts in-hospital adverse outcomes after primary PCI for ST-segment elevation myocardial infarction. Int J Cardiol. Apr 15;305:1-4.
Libby P. 2021. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. Nov 22;117(13):2525-2536.
Mengqi J, Shuangjun G, Shichao L, et al. 2021. Serum Lp PLA_ 2 Correlation analysis of GGT with coronary heart disease and severity of coronary artery disease. China New Clinical Medicine. 14 (02): 190-194.
Montone RA, Camilli M, Del Buono MG, et al. 2020. “No-reflow”: update su diagnosi, fisiopatologia e strategie terapeutiche [No-reflow: update on diagnosis, pathophysiology and therapeutic strategies]. G Ital Cardiol (Rome). Jun;21(6 Suppl 1):4S-14S.
Pantea-Roșan LR, Pantea VA, Bungau S, et al. 2020. No-Reflow after PPCI-A Predictor of Short-Term Outcomes in STEMI Patients. J Clin Med. Sep 12;9(9):2956.
Parma L, Peters HAB, Sluiter TJ, et al. 2020. bFGF blockade reduces intraplaque angiogenesis and macrophage infiltration in atherosclerotic vein graft lesions in ApoE3*Leiden mice. Sci Rep. Sep 29;10(1):15968.
Shihang Z, Man G, Feifei Z, et al. 2021. Predictive value of GRACE score combined with neutrophil/lymphocyte ratio for no reflow after PCI in patients with acute STEMI. Journal of Clinical Cardiovascular Diseases. 37(09): 810-815.
Song NP, Zhen XW, Li LD, et al. 2020. Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome. BMC Cardiovasc Disord. Oct 9;20(1):443.
Spaide RF, Fujimoto JG, Waheed NK, et al. 2018. Optical coherence tomography angiography. Prog Retin Eye Res. May;64:1-55.
Tasar O, Karabay AK, Oduncu V, et al. 2019. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. Jun;30(4):270-276.
Wang Z, Ren L, Liu N, et al. 2018. Utility of Hematological Parameters in Predicting No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost. Oct;24(7):1177-1183.
Weidong W, Zhen A, Shuangjun G, et al. 2018. PM_ (2.5) Research progress of exposure promoting the occurrence and development of atherosclerosis. Journal of Shandong University (Medical Edition). 56(11):18-26.
Wolf MP, Hunziker P. 2020. Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments. J Cardiovasc Transl Res. Oct;13(5):744-757.
Yajuan W. 2021. Correlation between plaque characteristics of ACS patients and coronary slow flow phenomenon. Zhongnan Journal of Medical Sciences. 49(03):335-339.
Yonetsu T, Jang IK. 2018. Advances in Intravascular Imaging: New Insights into the Vulnerable Plaque from Imaging Studies. Korean Circ J. Jan;48(1):1-15.
Zhen L, Qiaojuan W, Linlin L, et al. 2020. Diagnostic analysis of lipid index and plaque load on no reflow phenomenon during PCI in patients with ST segment elevation myocardial infarction. Journal of PLA Medicine. 32(06):73-76.
